Abstract: Vancomycin continuous infusion (CI) has suggested benefits over intermittent infusion: reduced nephrotoxicity, higher target attainment, and simpler therapeutic drug monitoring (TDM). Empiric dosing regimens range from 30-60 mg/kg/day and it is unclear which regimen results in optimal exposure. This study evaluates whether a dosing regimen of 45 mg/kg/day after a 20 mg/kg loading dose for patients with estimated glomerular filtration rate (eGFR) ≥ 50 mL/min results in adequate exposure. We retrospectively analyzed plasma concentrations from patients treated with vancomycin CI as routine clinical care between February and October 2021. Patients under 18 years old, with renal replacement therapy, reduced creatinine clearance (Chronic Kidney Disease Epidemiology Collaboration < 50 mL min/1.73 m 2 ) or outpatient antibiotic therapy were excluded. Dose, renal function, and blood draw procedures were assessed for each measured vancomycin sample. Initially, 121 samples were included. Subsequently, 7 samples, 6 of which with concentrations ≥ 40 mg/L, were verified to be incorrectly drawn and excluded. With doses of 40-50 mg/kg/day concentrations ranged from 18.4-61.0 mg/L. Only 25% were within the target window of 17-25 mg/L and 15% were ≥ 40 mg/L. Supratherapeutic concentrations were observed in 89% of samples from patients dosed 40-60 mg/kg/day with eGFR 50-80 mL/min. Concluding, an empiric dosing regimen of 45 mg/kg results in too high vancomycin exposure and thus we recommend lower doses and differentiation according to renal function. Additionally, when measuring concentrations over 40 mg/L incorrect sampling must be excluded before dose adjustment and the large variability in exposure between patients, warrants the need for swift TDM.
(© 2024 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
References: Hanrahan, T., Whitehouse, T., Lipman, J. & Roberts, J.A. Vancomycin‐associated nephrotoxicity: a meta‐analysis of administration by continuous versus intermittent infusion. Int. J. Antimicrob. Agents 46, 249–253 (2015).
Flannery, A.H., Bissell, B.D., Bastin, M.T., Morris, P.E. & Neyra, J.A. Continuous versus intermittent infusion of vancomycin and the risk of acute kidney injury in critically ill adults: a systematic review and meta‐analysis. Crit. Care Med. 48, 912–918 (2020).
Bissell, B.D., Riggi, G. & Morrison, C. Evaluation of continuous infusion vancomycin administration in a critically ill trauma population. J. Intensive Care Med. 35, 570–575 (2020).
Lee, B.V. et al. Cost‐benefit analysis comparing trough, two‐level AUC and Bayesian AUC dosing for vancomycin. Clin. Microbiol. Infect. 27, 1346.e1–1346.e7 (2021).
Rybak, M.J. et al. Therapeutic monitoring of vancomycin for serious methicillin‐resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 77, 835–864 (2020).
van Hal, S.J., Paterson, D.L. & Lodise, T.P. Systematic review and meta‐analysis of vancomycin‐induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob. Agents Chemother. 57, 734–744 (2013).
Hutschala, D., Kinstner, C., Skhirdladze, K., Thalhammer, F., Müller, M. & Tschernko, E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology 111, 356–365 (2009).
Wysocki, M. et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 45, 2460–2467 (2001).
Finch, N.A. et al. A quasi‐experiment to study the impact of vancomycin area under the concentration‐time curve‐guided dosing on vancomycin‐associated nephrotoxicity. Antimicrob. Agents Chemother. 61, e01293‐17 (2017).
Smit, C. et al. Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals. Br. J. Clin. Pharmacol. 86, 303–317 (2020).
Aljutayli, A., Marsot, A. & Nekka, F. An update on population pharmacokinetic analyses of vancomycin, part I: in adults. Clin. Pharmacokinet. 59, 671–698 (2020).
Processing Request
No Comments.